Immunotherapeutic approaches to HIV cure and remission
- PMID: 34873077
- DOI: 10.1097/QCO.0000000000000803
Immunotherapeutic approaches to HIV cure and remission
Abstract
Purpose of review: Despite improvements in the effectiveness of antiretroviral therapy (ART), there are still unmet needs for people living with HIV which drive the search for a cure for HIV infection. The goal of this review is to discuss the challenges and recent immunotherapeutic advances towards developing a safe, effective and durable cure strategy for HIV.
Recent findings: In recent years, advances have been made in uncovering the mechanisms of persistence of latent HIV and in developing more accurate assays to measure the intact proviral reservoir. Broadly neutralising antibodies and modern techniques to enhance antibody responses have shown promising results. Other strategies including therapeutic vaccination, latency reversal agents, and immunomodulatory agents have shown limited success, but newer interventions including engineered T cells and other immunotherapies may be a potent and flexible strategy for achieving HIV cure.
Summary: Although progress with newer cure strategies may be encouraging, challenges remain and it is essential to achieve a high threshold of safety and effectiveness in the era of safe and effective ART. It is likely that to achieve sustained HIV remission or cure, a multipronged approach involving a combination of enhancing both adaptive and innate immunity is required.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Katz IT, Ryu AE, Onuegbu AG, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc 2013; 16:18640.
-
- Thornhill J, Orkin C. Long-acting injectable HIV therapies: the next frontier:. Curr Opin HIV AIDS 2021; 16:98–105.
-
- Vansant G, Bruggemans A, Janssens J, Debyser Z. Block-and-lock strategies to cure HIV infection. Viruses 2020; 12:84.
-
- Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295–1300.
-
- Shan L, Deng K, Gao H, et al. Transcriptional reprogramming during effector-to-memory transition renders CD4+ T Cells permissive for latent HIV-1 infection. Immunity 2017; 47:766.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials